🔴 Moleculin Biotech is trading 10.72% down in pre-market

Moleculin Biotech is trading 10.72% lower in pre-market at $0.54, with no clear company-specific catalyst identified for the September 28 decline.

• Its September 25 announcement covered preclinical Annamycin findings presented at AACR; the company cautioned that preclinical results may not predict human outcomes.
• Broader markets were weaker: the Nasdaq Composite was down 1.07% and the S&P 500 was down 0.51%. Available evidence does not establish that macro sentiment caused the stock’s move.